BetterLife Pharma (TSE:BETR) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BetterLife Pharma has reported promising safety data for its lead drug candidate BETR-001, a non-hallucinogenic LSD derivative, showing no genotoxic effects. This positive outcome brings the company closer to starting clinical trials for this innovative treatment aimed at neuro-psychiatric and neurological disorders. Additionally, BetterLife has issued common shares and warrants through the conversion of its convertible debentures.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue